A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
    • 14 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2016.
    • 25 Apr 2016 Planned End Date changed from 1 Jan 2017 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top